Context (archaeology)

Intensive care medicine

Biology

Receptor

Immunity

Losartan

Paleontology

Immunology

Streptococcus pneumoniae

Immune system

Antibiotics

Angiotensin II

Microbiology

Internal medicine

Medicine

Pneumococcal infections

Colonization

Mucociliary clearance

Lung

American Journal of Respiratory and Critical Care Medicine

improved mucociliary clearance and mucous viscosity induced by losartan will enhance infection resolution.The question remains: is blocking CFTR function the perfect setting for the preclinical development of losartan?If not, what model really reproduces a reasonable, cost-effective means by which to explore specific therapies in the context of consistent and reproducible complexities of CF lung disease?Kim and colleagues' manuscript introduces the potential of losartan as a CF therapeutic and also highlights innovations in model development used for open-minded investigations and for the systematic development of novel therapeutics for CF.Innovation here is the key.

Improving Pulmonary Immunity to Bacterial Pathogens through <i>Streptococcus pneumoniae</i> Colonization of the Nasopharynx

Improving Pulmonary Immunity to Bacterial Pathogens through Streptococcus pneumoniae Colonization of the Nasopharynx